Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that has spread beyond the lungs to other parts of the body and is resistant to certain treatments like EGFR tyrosine kinase inhibitors.
Advanced Lung Cancer: STX-241 Study
We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have non-small cell lung cancer (NSCLC) that is locally advanced or metastatic?
- Have you had any major surgery or treatment for cancer in the past 3 months?
- Are you currently taking any medications that are strong CYP1A2 or CYP3A4 inducers or inhibitors, like certain antidepressants or antifungals?
- Do you have any history of serious lung problems like interstitial lung disease (ILD) or severe allergic reactions to medications?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Stx-241
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut De Cancerologie De L Ouest
Medical Oncology
Avignon, France
Hôpital de la Timone
Centre d'Essais en Cancerologie de Marseille (CEPCM - CLIPP)
Marseille, France
Centre Leon Berard
Medical Oncology
Meyzieu, France
Sponsor: Pierre Fabre Medicament
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.